Flo Health, the women’s health technology company behind one of the world’s most widely used menstrual cycle tracking applications, has announced a multi-year strategic partnership with Google Health aimed at integrating reproductive health information with wearable technology and personalized health coaching.
Google Health has also made a strategic investment in Flo, although the companies did not disclose the financial terms or the size of the investment.
The agreement will connect Flo’s menstrual and reproductive health tracking capabilities with Google’s wearable technology and health coaching services, allowing users to combine information about their menstrual cycles with physiological data collected throughout the day.
The integration is expected to begin in early 2027, subject to users’ explicit consent.
Flo reports more than 80 million monthly active users worldwide and approximately 500 million cumulative downloads since its launch more than a decade ago.
Combining Wearable Data With Reproductive Health Insights
The partnership will allow users who authorize the connection to synchronize information between Flo and Google Health.
Data collected through Fitbit devices, including sleep patterns, heart rate, heart rate variability, skin temperature and respiratory rate, will be incorporated into Flo’s cycle predictions and symptom analysis.
In the opposite direction, Flo’s reproductive health insights will become available within Google Health, allowing personalized coaching recommendations to account for menstrual cycle phases and different stages of reproductive life.
The companies intend to develop experiences covering menstruation, fertility, pregnancy, perimenopause and menopause.
Flo will become Google Health’s featured women’s health partner within its health application.
The integration reflects a broader development in consumer health technology, as wearable devices move beyond activity tracking toward services that combine physiological measurements with personalized health information.
Google Health Makes Strategic Investment in Flo
The investment represents an expansion of Google’s involvement in women’s health technology, a market that includes menstrual tracking, fertility services, pregnancy monitoring and digital health education.
Flo became a European femtech unicorn in 2024 following an investment from General Atlantic. The designation refers to privately held startups valued at $1 billion or more.
The company operates a subscription-based digital health platform offering menstrual and ovulation tracking, educational resources, symptom monitoring and personalized insights.
Its services are supported by a network of more than 100 medical experts, according to the company.
Under the new agreement, Flo will remain an independent business, with its founders and existing management continuing to oversee operations.
Beyond integrating their existing applications, Flo and Google Health plan to develop co-branded products combining reproductive health algorithms with wearable hardware and advanced sensor technology.
Neither company announced specific product launches or commercial pricing for those future offerings.
Artificial Intelligence Research to Focus on Women’s Health
A significant component of the partnership involves joint research into artificial intelligence models designed to account for hormonal changes and their effects on physiological indicators.
The companies plan to investigate relationships between hormonal fluctuations and measurements such as sleep, heart rate, mood and energy levels.
Their research agenda includes exploring whether AI models can identify patterns associated with early perimenopause and conditions such as polycystic ovary syndrome (PCOS), endometriosis and uterine fibroids.
These conditions can present symptoms that overlap with other health issues, potentially complicating diagnosis.
The companies also intend to study how wearable data might support fertility-related applications.
However, these initiatives remain research objectives rather than established diagnostic capabilities. Any potential clinical applications would require validation and, where applicable, regulatory review.
Flo and Google Health also plan to develop evaluation standards for AI-generated women’s health guidance, with an emphasis on clinical safety and reliability.
The research will use privacy-preserving approaches, including aggregated, pseudonymized and synthetic data, according to the companies.
Data Privacy and User Consent Become Central to the Agreement
The integration will involve sensitive health information, making data protection a significant component of the partnership.
Flo and Google Health said information will not move between their applications without users’ explicit authorization.
Consent will be requested separately for each category of information and its intended purpose, and users will be able to withdraw permission.
According to the companies, Flo data shared with Google Health will not be used for advertising, sold to third parties or made available to other applications and developers through Google’s health platforms.
These commitments are particularly relevant because menstrual cycles, fertility information and reproductive health records involve highly personal data.
The companies have not yet detailed every technical component of the planned integration or the specific controls that will be available when the service launches.
Women’s Health Becomes a Focus of Digital Health Investment
The partnership comes as technology companies expand the capabilities of wearable devices and invest in services that combine continuous monitoring with artificial intelligence.
For Flo, the agreement provides access to Google’s wearable technology and research capabilities while potentially extending its reach through a larger consumer technology ecosystem.
For Google Health, the investment provides access to Flo’s specialized reproductive health platform and its established international user base.
The collaboration also illustrates how digital health companies are seeking to develop more specialized services rather than relying exclusively on general fitness and wellness measurements.
The first phase of the integration is scheduled for early 2027. Future co-branded products and research-based applications will depend on development progress, clinical validation and applicable regulatory requirements.
